Study finds mitochondrial protein misfolding drives beta cell failure in T2D, making LONP1 a potential therapy target. Dr. Angelo Avogaro explains how incretin hormones support cardiovascular and metabolic health in type 2 diabetes treatment. Tirzepatide shows front-line potential in type 2 diabetes with heart disease, per Lilly’s SURPASS-CVOT outcomes trial. Dr. Neil Iyengar discusses how metabolic dysfunction impacts cancer risk, progression, and response to treatment. Emerging therapies targeting metabolism may improve cancer care and survivorship, Dr. Neil Iyengar explains. Over half of T2DM patients in primary care have MASLD; over 10% of those with obesity may have advanced fibrosis. Once-weekly semaglutide improved weight, insulin needs, and glycemic control in adults with T1D and obesity. Lifestyle and metformin interventions cut diabetes risk for 21 years in adults with prediabetes, DPP study shows. Tirzepatide linked to reduced muscle fat infiltration and volume in type 2 diabetes, per SURPASS-3 MRI substudy findings. Chronic hyperglycemia in pediatric type 1 diabetes may impair white matter development; brain changes persist into puberty. Higher HbA1c levels were a higher risk factor in children with lower BMIs. Trachtenberg's sudden death highlights the dangers of diabetes, including chronic and transplant-related complications. The two predictive models are called the Diabetes Remission Index and the Weight Loss-Adjusted Diabetes Remission Index. Estimates show that 2.2 million new cases of T2D and 1.2 million new cases of CVD are associated with sugary beverages. A study out of Ebril, Iraq, aimed to investigate psychological effects of erectile dysfunction in patients with diabetes. By collecting more deeply characterizing data, the research group hopes to create pseudo health histories around T2D. The high-HGI group exhibited lower TIR and greater time below range with higher A1c than the low-HGI group. One plus side to social media use is accessibility to information for patients with diabetes. There are significant challenges in achieving diabetes control in patients with both diabetes and HIV. Renal dysfunction increases the risk of MACEs in patients with type 2 diabetes mellitus.